Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that
immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively …

Resistance to immune checkpoint inhibitors (ICIs) is a common predicament in cancer
immunotherapy, which requires urgent interventions. V-domain immunoglobulin suppressor …

V-type immunoglobulin domain-containing suppressor of T cell activation (VISTA) is
considered as an immunosuppressive factor and potential therapeutic target for anticancer …

In recent years, tumor immunotherapy has become an active research area, with the
emergence of immune checkpoint inhibitors (ICIs) revolutionizing immunotherapy. Clinical …

Multiple myeloma (MM) is a hematological malignancy originating from plasma cells.
Genetically, MM is categorized into two subtypes: hyperdiploid and non-hyperdiploid tumors …

Amyloid light chain (AL) amyloidosis is a rare plasma cell dyscrasia with dismal prognosis.
This study aims to investigate the T-cell immune checkpoint expression patterns in systemic …

Esophageal squamous cell carcinoma (ESCC) is the most common type of esophageal
carcinoma (EC) in China. Although the PD-1 inhibitor pembrolizumab has been approved to …

Multiple myeloma (MM), a cancer of the bone marrow, is categorized as the second most
common hematological malignancy of adults in the Western world. Despite dramatic …

Background: Multiple Myeloma is a hematological malignancy characterized by the
proliferation of clonal plasma cells and associated with severe clinical manifestations …

Cancer immune function and tumor microenvironment are governed by long noncoding
RNAs (lncRNAs). Nevertheless, it has yet to be established whether lncRNAs play a role in …